Pfizer may have a lot going on in immunology, but all its drugs could be beaten by rivals: analyst

Pfizer’s immunology portfolio includes the JAK inhibitor Xeljanz and a pipeline of five mid- to late-stage experimental drugs—a huge stable of assets that seems well-positioned to fuel strong growth over the next five years.

But one influential Wall Street firm took a deep dive into that immunology portfolio and found a troublesome undercurrent that made its analysts wonder just how much it will really contribute to Pfizer’s future growth